3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioma
1
Diffuse Intrinsic Pontine Glioma
1
Brain Neoplasms
1
Interventions
Temozolomide
3
Panobinostat
2
Cyclophosphamide
2
Bevacizumab
2
ribociclib
1
marizomib
1
dipinacoline glutamate
1
cemiplimab
1
Topotecan
1
TIC10 compound
1
Re-Irradiation
1
Radiotherapy
1
Radiation
1
Maintenance
1
Irinotecan
1
Imiquimod
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Erlotinib Hydrochloride
1
Drug Tolerance
1
Doxorubicin
1
Diphtheria-Tetanus Vaccine
1
Congresses as Topic
1
Cilengitide
1
Cetuximab
1
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Diffuse Intrinsic Pontine Glioma
×
Drug Tolerance
×
Clear all
NCT04771897
2024-12-20
KONQUER
Bexion Pharmaceuticals, Inc.
Phase 1
Terminated
10 enrolled